Effects of losartan on cerebral and ocular circulation in healthy subjects

British Journal of Clinical Pharmacology

Volumn 44, Issue 4, 1997, Pages 369-375

  Matulla, Bettina ^a   Streit, Gabriele ^a   Pieh, Stefan ^a   Findl, Oliver ^a   Entlicher, Jesusa ^a   Graselli, Ursula ^a   Eichler, Hans Georg ^a   Wolzt, Michael ^a   Schmetterer, Leopold ^a,b  

^a Department of Clinical Pharmacology ^*  (Austria)

^b Institute for Medical Physics   (Austria)

Author keywords

Angiotensin II; Cerebral blood flow; Doppler sonography; Fundus pulsation; Losartan; Ocular blood flow

Indexed keywords

ANGIOTENSIN; LOSARTAN; PLACEBO;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BRAIN BLOOD FLOW; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPPLER ECHOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EYE BLOOD FLOW; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VOLUNTEER;

EID: 0030807322     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00598.x     Document Type: Article

References (38)

1. Brunner HR, Nussberger J, Waeber B. Effects of angiotensin converting enzyme inhibition: a clinical point of view. J Cardiovasc Pharmacol 1985; 7(suppl. 4): 73-81.
2. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
3. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
4. Timmermans PB, Wong PC, Chiu AT, Smith RD. The preclinical basis of the therapeutic evaluation of losartan. J Hypertension 1995; 13(suppl. 1): S1-S13.
5. Edvinsson L, Hardebo JE, Owan C. Effects of angiotensin II on cerebral blood vessels. Acta Physiol Scand 1979; 105: 381-383.
6. Haberl RL. Role of angiotensin receptor subtypes in the response of rabbit brain arterioles to angiotensin. Stroke 1994; 25: 1476-1480.
7. Igic R, Kojovic V. Angiotensin I converting enzyme (kinase II) in ocular tissues. Exp Eye Res 1980; 30: 299-303.
8. Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin II binding receptors in retinal and optic nerve head blood vessels. Invest Ophthalmol Vis Sci 1991; 32: 21-26.
9. Berg Nyborg NC, Nielsen PJ, Prieto D, Benedito S. Angiotensin II does not contract bovine retinal resistance arteries in vivo. Exp Eye Res 1990; 50: 469-474.
10. Berg Nyborg NC, Nielsen PJ. Angiotensin II contracts isolated human posterior ciliary arteries. Invest Ophthalmol Vis Sci 1990; 31: 2471-2473.
11. Demolis P, Chalon S, Annane D, Duhaze P, Guidicelli JF. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteer. Br J Clin Pharmacol 1992; 34: 224-230.
12. Demolis P, Carville C, Guidicelli JF. Effects of angiotensin-converting enzyme inhibitor, lisinopril, on cerebral blood flow autoregulation in healthy volunteers. J Cardiovasc Pharmacol 1993; 22: 373-380.
13. Krejcy K, Wolzt M, Kreuzer C, Breiteneder H, Schütz W, Eichler HG, Schmetterer L. Characterisation of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods. Br J Clin Pharmacol 1997; 43: 501-508.
14. Aaslid R, Markwalder TM, Nornes H. Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 1982; 57: 769-774.
15. Guchoff RE, Berger RW, Winkler P, Helmke K, Chumbley LC. Doppler ultrasonography of the ophthalmic and central retinal vessels. Arch Ophthalmol 1991; 109: 532-536.
16. Schmetterer L, Lexer F, Unfried C, Sattmann H, Fercher A. Topical measurement of fundus pulsations. Opt Eng 1995; 34: 711-716.
17. Schmetterer L, Wolzt M, Salomon A, et al. Effect of isoproterenol, phenylephrine, and sodium nitroprusside on fundus pulsations in healthy volunteers. Br J Ophthalmol 1996; 80: 217-223.
18. Schmetterer L, Strenn K, Findl O, et al. Effects of antiglaucoma drugs on ocular hemodynamics in healthy volunteers. Clin Pharmacol Ther 1997; 61: 583-595.
19. Langham ME, Tomey K. A clinical procedure for the measurement of the ocular pulse-pressure relationship and the ophthalmic arterial pressure. Exp Eye Res 1978; 27: 17-25.
20. Langham ME, Farrell RA, O'Brien V, Silver DM, Schilder P. Blood flow in the human eye. Acta Ophthalmol 1989; 67(Suppl. 191): 9-13.
21. Schmetterer L, Wolzt M, Lexer F, et al. The effect of hyperoxia and hypercapnia on fundus pulsations in the macular and optic disc region in healthy young volunteers. Exp Eye Res 1995; 61: 685-690.
22. 2 on ocular fundus pulsations. Exp Eye Res 1996; 63: 351-355.
23. Pourcelot L. Diagnostic ultrasound for cerebral vascular diseases; In Present and future of diagnostic ultrasound. Eds. Donald I, Levi S Rotterdam, The Netherlands: Kooyker 1976: 141-147.
24. Hayreh SS, Beach KW. Optic nerve head sheath decompression, comment. Ophthalmology 1993; 100: 303-305.
25. Strandgaard S, Paulsen OB. Regulation of cerebral blood flow in health and disease. J Cardiovasc Pharmacol 1992; 19(Suppl. 6): S89-93.
26. Krakau CET. A model for pulsatile and steady ocular blood flow. Graefes Arch Clin Exp Ophthalmol 1995; 233: 112-118.
27. Costagliola C, Di Bendetto R, De Caprio L, Verde R, Mastropasqua L. Effect of oral captopril on intraocular pressure in man. Eur J Ophthalmol 1995; 5: 19-25.
28. Karzneis TA, Murphy MB, Weber RR, Nelson KS, Tripathi BJ, Tripathi RC. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res 1988; 47: 689-697.
29. Maepea O. Pressures in the anterior ciliary arteries, choroidal veins and choriocapillaris. Exp Eye Res 1992; 54: 731-736.
30. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers. Circulation 1991; 83: 1333-1342.
31. Goldberg MR, de Mey C, Wroblewski JM, Li Q, Schroeter V, Belz GG. Differential effects of losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men. Clin Pharmacol Ther 1995; 59: 72-82.
32. Munafo A, Christen Y, Nussberger J, et al. Drug concentration-response relationship in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-521.
33. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290-297.
34. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active receptor metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
35. Rossi G, Rossi A, Sacchetto A, Pavan E, Pessina A. Hypertensive cerebrovascular disease and the renin-angiotensin system. Stroke 1995; 26: 1700-1706.
36. Fornes P, Richter C, Vacher E, Bruneval P, Giudicelli JF. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22: 305-313.
37. Kiel JW. Choroidal myogenic autoregulation and intraocular pressure. Exp Eye Res 1994; 58: 529-544.
38. 2 receptor stimulation extends the upper limit of cerebral blood flow autoregulation: agonist effects of CGP 42112 and PD 123319. J Cereb Blood Flow Metab 1994; 14: 38-44.